Étude Comparée sur la Réussite Universitaire Québec-Ontario pour la Période 1994-1996

The knowledge-based economy has emphasised the role of human capital and the relevance of formal education. This study analyses university achievement and gives a quantitative description of Quebec and Ontario university systems. Comparative differences by educational levels and fields of studies are presented and discussed within the context of the labour market. Les préoccupations actuelles de l'économie du savoir ont mis en valeur l'importance du capital humain et par conséquent l'importance de l'instruction. Cette étude analyse la réussite universitaire et permet de décrire d'un point de vue quantitatif les systèmes universitaires québécois et ontariens. Le point de vue qualitatif est également traité à travers l'analyse des différences par domaine d'étude et par discipline.university achievement, educational levels, fields of studies, rate of return, sectors of activity, réussite universitaire, baccalauréat, maîtrise, doctorat, domaine d'étude, matières, postsecondaire, écarts, taux de rendement, secteur d'activité

Régénération continue des bains de PEG utilisés pour la consolidation des bois archéologiques gorgés d’eau

ARC-Nucléart a élaboré un système de régénération des bains de polyéthylène glycol (PEG), utilisés dans le traitement de consolidation des bois archéologiques gorgés d’eau et progressivement pollués par différentes bactéries, par les substances dissoutes et les particules apportées par les bois eux-mêmes. La nouveauté de cette approche est le remplacement de l’usage des biocides par l’extraction et la neutralisation des contaminants et ce suivant quatre axes : le retrait des particules et des levures par micro-filtration, celui des ions par résines à lit fluidisé, la désinfection de la solution de PEG par passage devant une lampe UVc et l’aération des bains. Ces mesures permettent de régénérer les bains et donc de réduire sensiblement l’impact économique et environnemental des traitements tout en améliorant leur qualité.ARC-Nucléart has developed a system for regenerating PEG (polyethylene glycol) baths, used in the treatment for consolidating waterlogged archaeological wood progressively degraded by bacteria, by substances that have dissolved in the water and by particles added by the wood itself. The novelty of this approach lies in its method of replacing the use of biocides with a fourfold method of extraction and neutralizing contaminants: removal of particules and yeasts by micro-filtration; removal of ions by fluidized beds of resin/activated charcoal; disinfection of the PEG solution by running it past an UVC lamp and by air bullage (oxygenation) of baths. Using these measures to regenerate the baths markedly reduces the economic and environmental impact of the treatments at the same time as improving their quality

Identification of Spectral Modifications Occurring during Reprogramming of Somatic Cells

Recent technological advances in cell reprogramming by generation of induced pluripotent stem cells (iPSC) offer major perspectives in disease modelling and future hopes for providing novel stem cells sources in regenerative medicine. However, research on iPSC still requires refining the criteria of the pluripotency stage of these cells and exploration of their equivalent functionality to human embryonic stem cells (ESC). We report here on the use of infrared microspectroscopy to follow the spectral modification of somatic cells during the reprogramming process. We show that induced pluripotent stem cells (iPSC) adopt a chemical composition leading to a spectral signature indistinguishable from that of embryonic stem cells (ESC) and entirely different from that of the original somatic cells. Similarly, this technique allows a distinction to be made between partially and fully reprogrammed cells. We conclude that infrared microspectroscopy signature is a novel methodology to evaluate induced pluripotency and can be added to the tests currently used for this purpose

Classification of the fibronectin variants with curvelets

International audienceThe role of the extracellular matrix (ECM) in the evolution of certain diseases (e.g. fibrosis, cancer) is generally accepted but yet to be completely understood. A numerical model that captures the physical properties of the ECM, could convey certain connections between the topology of its constituents and their associated biological features. This study addresses the analysis and modeling of fibrillar networks containing Fibronectin (FN) networks, a major ECM molecule, from 2D confocal microscopy images. We leveraged the advantages of the fast discrete curvelet transform (FDCT), in order to obtain a multiscale and multidirectional representation of the FN fibrillar networks. This step was validated by performing a classification among the different variants of FN upregulated in disease states with a multi-class classification algorithm, DAG-SVM. Subsequently, we designed a method to ensure the invariance to rotation of the curvelet features. Our results indicate that the curvelets offer an appropriate discriminative model for the FN networks, that is able to characterize the local fiber geometry

Sélection des sites et des proies par les Barges à queue noire Limosa limosa islandica s’alimentant sur les herbiers de zoostères et les vasières du centre de la côte atlantique française

Characeae surveys and water physico-chemical studies have been performed during four years (2007-2011) on 41 wetlands of Numidia (NE Algeria). Among the 12 species inventoried in the region, four are rare in North Africa and one, Nitella batrachosperma, is new for Algeria. Comparison between Characeae communities and phosphate contents shows that (1) Characeae have nearly disappeared from habitats that contain high levels of orthophosphates (> 780 μg.l-1), (2) three species of Chara (C. globularis, C. gymnophylla and C. vulgaris) characterize medium-polluted habitats (213-780 μg.l-1), where they are often present as discontinuous populations, and (3) the Nitella (N. opaca and N. translucens) are good indicators of low water pollution (< 70 μg.l-1). In addition to the sole presence of a given species, the physiological appearance of the plants has to be taken into consideration as a sign of a healthy population.Dans une population en expansion, certains individus sont voués à explorer et exploiter de nouveaux habitats de moindre qualité. Sur la façade ouest européenne, la Barge à queue noire Limosa limosa islandica, qui se reproduit exclusivement en Islande, est l’une des rares espèces de limicoles avec une tendance démographique positive. Les côtes françaises accueillent 28 % de la population au milieu de l’hiver, le reste se distribuant sur les îles britanniques et la péninsule ibérique. Contrairement à la Grande Bretagne et l’Irlande, la population française se concentre sur un nombre restreint de sites mais avec de fortes concentrations. Les Pertuis Charentais accueillent plus de 65 % de la population nationale (ca 18 000 individus). Dans cette étude, nous décrivons comment la sélection des proies et les stratégies d’alimentation en milieux intertidaux sont liées à la sélection des sites à l’échelle locale and peuvent expliquer la distribution des oiseaux en période de non reproduction. La sélection des sites et des espèces-proies par les barges a été étudiée par la description du régime alimentaire et de la ressource trophique sur six zones d’alimentation sur les quatre principaux sites hivernages. Dans les Pertuis Charentais, il a été confirmé que ces barges occupent une niche écologique herbivore sur le nouveau site d’hivernage de l’île de Ré, où elles s’alimentent de Zostères naines Zostera noltii. La barge garde un régime carnivore sur les sites continentaux, où elle s’alimente principalement du bivalve Macoma balthica. Sur ces sites, les barges ciblent la proie la plus rentable. À l’exception du dérangement humain, la distribution des individus dans les Pertuis Charentais semble être déterminée par la distribution, l’abondance et l’accessibilité de seulement deux espèces-proies parmi un large éventail d’espèces benthiques

Evidence for the Contribution of the Hemozoin Synthesis Pathway of the Murine Plasmodium yoelii to the Resistance to Artemisinin-Related Drugs

Plasmodium falciparum malaria is a major global health problem, causing approximately 780,000 deaths each year. In response to the spreading of P. falciparum drug resistance, WHO recommended in 2001 to use artemisinin derivatives in combination with a partner drug (called ACT) as first-line treatment for uncomplicated falciparum malaria, and most malaria-endemic countries have since changed their treatment policies accordingly. Currently, ACT are often the last treatments that can effectively and rapidly cure P. falciparum infections permitting to significantly decrease the mortality and the morbidity due to malaria. However, alarming signs of emerging resistance to artemisinin derivatives along the Thai-Cambodian border are of major concern. Through long-term in vivo pressures, we have been able to select a murine malaria model resistant to artemisinins. We demonstrated that the resistance of Plasmodium to artemisinin-based compounds depends on alterations of heme metabolism and on a loss of hemozoin formation linked to the down-expression of the recently identified Heme Detoxification Protein (HDP). These artemisinins resistant strains could be able to detoxify the free heme by an alternative catabolism pathway involving glutathione (GSH)-mediation. Finally, we confirmed that artemisinins act also like quinolines against Plasmodium via hemozoin production inhibition. The work proposed here described the mechanism of action of this class of molecules and the resistance to artemisinins of this model. These results should help both to reinforce the artemisinins activity and avoid emergence and spread of endoperoxides resistance by focusing in adequate drug partners design. Such considerations appear crucial in the current context of early artemisinin resistance in Asia

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

[Excerpt] Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [2]. The somatic mutational landscape of sporadic MM has been increasingly investigated, aiming to identify recurrent genetic events involved in myelomagenesis. Whole exome and whole genome sequencing studies have shown that MM is a genetically heterogeneous disease that evolves through accumulation of both clonal and subclonal driver mutations [3] and identified recurrently somatically mutated genes, including KRAS, NRAS, FAM46C, TP53, DIS3, BRAF, TRAF3, CYLD, RB1 and PRDM1 [3,4,5]. Despite the fact that family-based studies have provided data consistent with an inherited genetic susceptibility to MM compatible with Mendelian transmission [6], the molecular basis of inherited MM predisposition is only partly understood. Genome-Wide Association (GWAS) studies have identified and validated 23 loci significantly associated with an increased risk of developing MM that explain ~16% of heritability [7] and only a subset of familial cases are thought to have a polygenic background [8]. Recent studies have identified rare germline variants predisposing to MM in KDM1A [9], ARID1A and USP45 [10], and the implementation of next-generation sequencing technology will allow the characterization of more such rare variants. [...]French National Cancer Institute (INCA) and the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFMRG), the Intergroupe Francophone du Myélome (IFM), NCI R01 NCI CA167824 and a generous donation from Matthew Bell. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD018522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank the Association des Malades du Myélome Multiple (AF3M) for their continued support and participation. Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organizatio

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.

BACKGROUND: Familial ovarian cancer (OC) cases not harbouring pathogenic variants in either of the BRCA1 and BRCA2 OC-predisposing genes, which function in homologous recombination (HR) of DNA, could involve pathogenic variants in other DNA repair pathway genes. METHODS: Whole exome sequencing was used to identify rare variants in HR genes in a BRCA1 and BRCA2 pathogenic variant negative OC family of French Canadian (FC) ancestry, a population exhibiting genetic drift. OC cases and cancer-free individuals from FC and non-FC populations were investigated for carrier frequency of FANCI c.1813C>T; p.L605F, the top-ranking candidate. Gene and protein expression were investigated in cancer cell lines and tissue microarrays, respectively. RESULTS: In FC subjects, c.1813C>T was more common in familial (7.1%, 3/42) than sporadic (1.6%, 7/439) OC cases (P = 0.048). Carriers were detected in 2.5% (74/2950) of cancer-free females though female/male carriers were more likely to have a first-degree relative with OC (121/5249, 2.3%; Spearman correlation = 0.037; P = 0.011), suggesting a role in risk. Many of the cancer-free females had host factors known to reduce risk to OC which could influence cancer risk in this population. There was an increased carrier frequency of FANCI c.1813C>T in BRCA1 and BRCA2 pathogenic variant negative OC families, when including the discovery family, compared to cancer-free females (3/23, 13%; OR = 5.8; 95%CI = 1.7-19; P = 0.005). In non-FC subjects, 10 candidate FANCI variants were identified in 4.1% (21/516) of Australian OC cases negative for pathogenic variants in BRCA1 and BRCA2, including 10 carriers of FANCI c.1813C>T. Candidate variants were significantly more common in familial OC than in sporadic OC (P = 0.04). Localization of FANCD2, part of the FANCI-FANCD2 (ID2) binding complex in the Fanconi anaemia (FA) pathway, to sites of induced DNA damage was severely impeded in cells expressing the p.L605F isoform. This isoform was expressed at a reduced level, destabilized by DNA damaging agent treatment in both HeLa and OC cell lines, and exhibited sensitivity to cisplatin but not to a poly (ADP-ribose) polymerase inhibitor. By tissue microarray analyses, FANCI protein was consistently expressed in fallopian tube epithelial cells and only expressed at low-to-moderate levels in 88% (83/94) of OC samples. CONCLUSIONS: This is the first study to describe candidate OC variants in FANCI, a member of the ID2 complex of the FA DNA repair pathway. Our data suggest that pathogenic FANCI variants may modify OC risk in cancer families

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570